-

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

  • Truist Securities BioPharma Symposium, November 6, 2025
  • Stifel Healthcare Conference, November 11-13, 2025
  • Jefferies Global Healthcare Conference, November 18-20, 2025
  • Piper Sandler 37th Annual Healthcare Conference, December 2-4, 2025

Visit AbCellera's Investor Relations website for additional information.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com.

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Industry:

AbCellera Biologics Inc.

NASDAQ:ABCL
Release Summary
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
Release Versions
English
$Cashtags
$ABCL

Contacts

Inquiries
Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
AbCellera on LinkedIn
AbCellera on Twitter
More News From AbCellera Biologics Inc.

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

DUBLIN & VANCOUVER, British Columbia--(BUSINESS WIRE)--Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies...

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Appoints Dr. Victor Sandor to its Board of Directors...

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635...
Back to Newsroom